08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis MicroRNA-214 (miR-214) In vitro and mouse studies suggest inhibiting miR-214...
07:00 , Apr 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury MicroRNA-214 (miR-214) Mouse studies suggest increasing miR-214 levels...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

VioQuest preclinical data

In vitro VQD-002, a tricyclic nucleoside that inhibits Akt phosphorylation, reduced cancer cell survival with or without cisplatin. Also, the microRNA miR-214 activated the Akt pathway and induced ovarian cancer cell survival and cisplatin resistance....